BioNTech is having its Pfizer moment

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with yet another megaround in biotech, a preview of some hotly anticipated data, and the perils of declining revenue.

The need-to-know this morning

• Roche and its partner Chugai said Enspryng, their IL-6-targeted antibody treatment, “did not reach our expectations on the degree of clinical benefit” in a Phase 3 study of the autoimmune disorder myasthenia gravis.
• Shares of Argenx reacted positively to the Enspryng setback. Argenx’s FcRN-targeted antibody drug, Vyvgart, is approved to treat patients with myasthenia gravis. Shares of Immunovant, developing its own FcRN antibody, were also up. Tourmaline Bio, maker of an IL-6 antibody, saw its stock price fall.

After an $11 billion sale, the team behind Prometheus has a new startup

And it just raised $400 million to, like its predecessor, develop new medicines for inflammatory diseases.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In